Navigation Links
Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
Date:3/20/2017

Avexegen Therapeutics Inc., an innovative biotechnology company developing novel therapies for gastrointestinal (GI) disorders, today announced that it has entered into an exclusive global license agreement with Children’s Hospital Los Angeles (CHLA) for Neuregulin-4 (NRG-4) for therapies in inflammatory bowel disease including Necrotizing Enterocolitis (rare orphan disease) as well as Crohn’s Disease and Ulcerative Colitis.

“With this licensing deal, Avexegen will continue to advance on its strategy to develop therapies for high unmet need GI disorders,” said Artin Asadourian, CEO of Avexegen Therapeutics.

Mark Frey, PhD, a principal investigator at The Saban Research Institute of CHLA, has demonstrated NRG-4 therapeutic proof of concept in preclinical models of NEC and inflammatory bowel disease. NRG-4’s efficacy is mediated by dual mechanisms that promote mucosal healing: the direct protection of the intestinal barrier and the suppression of inflammatory cytokines via its novel immunomodulatory action.

Currently, there are no FDA approved drugs for the treatment or prevention of Necrotizing Enterocolitis (NEC), which is a life-threatening disease that afflicts very low birth weight premature infants. NRG-4 has the potential to be the first such therapy for NEC.

About Avexegen Therapeutics, Inc.
Avexegen, founded in December 2014, is an emerging privately held biotech company based in San Diego, CA focused on developing novel treatments for a broad spectrum of inflammatory GI disorders. For more information please visit http://www.avexegen.com

Read the full story at http://www.prweb.com/releases/2017/03/prweb14155590.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference
2. eFFECTOR Therapeutics Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma
3. Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
4. Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017
5. UNIAPAC Foundation Think Tank in Paris selects Renova Therapeutics CEO and Co-founder as keynote speaker for annual meeting
6. Envisia Therapeutics To Present At American Glaucoma Society 2017 Annual Meeting
7. Stealth BioTherapeutics Initiates Observational Study of Patients With Mitochondrial Myopathy
8. Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th Annual Health Care Conference
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
10. Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
11. Capricor Therapeutics to Present at Two Investor Conferences in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced the ... NIH to develop RealSeq®-SC (Single Cell), expected to be ... small RNAs (including microRNAs) from single cells using NGS ... the need to accelerate development of approaches to analyze ... "New techniques for measuring levels of mRNAs ...
(Date:10/9/2017)... ... , ... The award-winning American Farmer television series will feature 3 Bar Biologics ... at 8:30aET on RFD-TV. , With global population estimates nearing ten billion people ... to feed a growing nation. At the same time, many of our valuable resources ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
Breaking Biology News(10 mins):